<PAGE>
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): July 10, 2000
--------------------
GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 0-10824 04-2297484
(State or other jurisdiction (Commission File (I.R.S. Employer
of incorporation) Number) Identification Number)
100 BEAVER STREET
WALTHAM, MASSACHUSETTS 02453
(Address, of principal executive offices, including zip code)
(781) 398-2300
(Registrant's Telephone number including area code)
--------------------
--------------------------------------------------------------------------------
Page 1 of 5 pages.
<PAGE>
Item 5. OTHER EVENTS
On July 10, 2000, Genome Therapeutics Corp. issued a press release
announcing that the Company raised $44.7 million in additional capital. A copy
of this press release is attached to this Current Report on Form 8-K as Exhibit
99.1.
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENOME THERAPEUTICS CORP.
By /s/ Philip V. Holberton
----------------------------------
Name: Philip V. Holberton
Title: Chief Financial Officer
Date: July 10, 2000
-3-
<PAGE>
EXHIBIT INDEX
99.1 Press Release dated July 10, 2000
-4-
